Investigating how incretin mimetics affect cancer development in the pancreas
Official title: Targeting pancreatic endocrine-exocrine signaling in cancer development with incretin mimetics
Funded at Yale University · NIH-11024645 · Data updated 2026-11-12
This study is looking at whether medications called GLP-1 receptor agonists, which help with weight loss and diabetes, might affect the risk of developing a serious type of pancreatic cancer in people who are already at higher risk due to obesity and diabetes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | February 1, 2025 |
| Project end | December 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $693,075 |
| NIH project number | 1R01CA296916-01 |
| Project ID | NIH-11024645 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with obesity and diabetes who are considering or currently using GLP-1 receptor agonists.
✕Less likely to help
Patients without obesity or diabetes, or those not using GLP-1 receptor agonists, may not benefit from this research.
What this research studies
This research explores the effects of incretin mimetics, specifically glucagon-like peptide-1 receptor agonists (GLP-1RAs), on the risk of developing pancreatic ductal adenocarcinoma (PDAC), a severe form of cancer. The study aims to clarify whether these medications, commonly used for obesity and diabetes, influence cancer risk, particularly in patients with obesity and diabetes who are already at higher risk for PDAC. By examining the biological mechanisms involved, the research seeks to provide insights into how these drugs may impact pancreatic health and cancer progression. Patients may benefit from a better understanding of the safety and efficacy of GLP-1RAs in relation to cancer risk.
Why it matters
Potential benefit: If successful, this research could lead to safer treatment options for obesity and diabetes that do not increase the risk of pancreatic cancer.
How similar studies have gone: While there have been studies on GLP-1RAs and their effects, this research aims to provide novel insights specifically regarding their role in pancreatic cancer risk.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Muzumdar, Mandar Deepak — Yale University
- Study coordinator: Muzumdar, Mandar Deepak
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.